Stockscreener 앱 받기
1.73
15.33%
0.23
시간 외 거래:
1.72
-0.01
-0.58%
전일 마감가:
$1.50
열려 있는:
$1.5
하루 거래량:
2.83M
Relative Volume:
2.91
시가총액:
$95.39M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
-1.0949
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
+26.28%
1개월 성능:
+35.16%
6개월 성능:
+7.45%
1년 성능:
-39.93%
1일 변동 폭
$1.48
$1.75
1주일 범위
$1.27
$2.05
52주 변동 폭
$0.8301
$2.91
Regulus Therapeutics Inc Stock (RGLS) Company Profile
명칭
Regulus Therapeutics Inc
전화
858-202-6300
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.73 | 95.39M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-03-18 | 개시 | Leerink Partners | Outperform |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 개시 | Leerink Partners | Outperform |
| 2017-06-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-06 | 재확인 | Wedbush | Outperform |
| 2017-01-30 | 다운그레이드 | Needham | Buy → Hold |
| 2017-01-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-11-02 | 재확인 | Needham | Buy |
| 2016-07-25 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | FBR Capital | Outperform |
| 2016-06-28 | 재확인 | Needham | Buy |
| 2016-06-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-04-13 | 개시 | Chardan Capital Markets | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2015-04-21 | 재개 | FBR Capital | Outperform |
| 2014-11-24 | 개시 | Deutsche Bank | Buy |
| 2014-08-07 | 재확인 | FBR Capital | Outperform |
| 2013-08-14 | 재확인 | Needham | Buy |
모두보기
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - Marketscreener.com
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider.com
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - Marketscreener.com
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - StockTitan
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
Regulus: Q4 Earnings Snapshot - The Bakersfield Californian
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - StockTitan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - Simply Wall St
Insider Buying: David Baltimore Acquires Shares of Regulus Thera - GuruFocus.com
Regulus Therapeutics Inc (RGLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):